2021 / 06

Next Paper
DOI: 10.24075/brsmu.2021.065
Copyright: © 2021 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Metabolic “footprints” of the circulating cancer mucins: CA125 in the high-grade ovarian cancer

Chagovets VV1, Vasil'ev VG2, Iurova MV1,3, Khabas GN1, Pavlovich SV1,3, Starodubtseva NL1, Mayboroda OA4,5
About authors

1 Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia

2 Peoples’ Friendship University of Russia, Moscow, Russia

3 Sechenov First Moscow State Medical University, Moscow, Russia

4 Leiden University Medical Center, Leiden, The Netherlands

5 Tomsk State University, Tomsk, Russia

Correspondence should be addressed: Vitaly V. Chagovets
Akademika Oparina, 4, Moscow, 117997, Russia; moc.liamg@stevogahcvv

About paper

Funding: the study was supported by a grant from the Russian Science Foundation (project #20-65-46014).

Author contribution: Chagovets VV — study planning, sample preparation, discussion of NMR data processing, manuscript authoring and editing; Vasil'ev VG — sample preparation, NMR analysis; Iurova MV, Khabas GN — collection and characterization of clinical samples, discussion of the results; Pavlovich SV — study research, discussion of the results; Starodubtseva NL — study planning, clinical data processing; Mayboroda OA — study planning and management, manuscript authoring, NMR data processing.

Compliance with ethical standards: the study was approved by the Ethics Committee of the V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology (Minutes #10 of December 05, 2019), conducted in accordance with federal laws of the Russian Federation (#152, 323 etc.) and the Declaration of Helsinki of 1964 with all subsequent extensions and amendments regulating scientific research involving biomaterials obtained from human beings.

Received: 2021-12-01 Accepted: 2021-12-16 Published online: 2021-12-29
|
  1. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004; 4 (1): 45–60. DOI: 10.1038/NRC1251.
  2. Yin BWT, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J cancer. 2002; 98 (5): 737–40. DOI: 10.1002/IJC.10250.
  3. Devine PL, McGuckin MA, Ward BG. Circulating mucins as tumor markers in ovarian cancer (review). Anticancer Res. 1992; 12 (3): 709–17. Accessed November 27, 2021. Available from: https:// www.researchgate.net/publication/21533861_Circulating_ mucins_as_tumor_markers_in_ovarian_cancer_Review.
  4. Pavlovich SV, Yurova MV, Melkumyan AG, Frankevich VE, Chagovets VV, Khabas GN. Biomarkers in ovarian neoplasms: opportunities, limitations, and prospects for using in reproductiveaged women. Akush Ginekol (Sofiia). 2019; 11 (2019): 65–73. DOI: 10.18565/aig.2019.11.65–73.
  5. Felder M, Kapur A, Gonzalez-Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13 (1): 1–15. DOI: 10.1186/1476-4598-13-129.
  6. Seyfried TN, Flores RE, Poff AM, D’Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014; 35 (3): 515. DOI:10.1093/CARCIN/BGT480.
  7. Coller HA. Is Cancer a Metabolic Disease? Am J Pathol. 2014; 184 (1): 4. DOI:10.1016/J.AJPATH.2013.07.035.
  8. Kaprin AD, Starinskij VV, Shahzadova AO, redaktory. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2019 godu. M.: MNIOI im. P. A. Gercena — filial FGBU «NMIC radiologii», 2020; 239 s.
  9. Psychogios N, Hau DD, Peng J, et al. The Human Serum Metabolome. PLoS One. 2011; 6 (2): e16957. DOI: 10.1371/ JOURNAL.PONE.0016957.
  10. Dorokhov YL, Shindyapina AV, Sheshukova EV, Komarova TV. Metabolic methanol: molecular pathways and physiological roles. Physiol Rev. 2015; 95 (2): 603–44. DOI: 10.1152/PHYSREV.00034.2014.
  11. Tang WHW, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015; 116 (3): 448–55. DOI: 10.1161/CIRCRESAHA.116.305360.
  12. Lai HS, Lee JC, Lee PH, Wang ST, Chen WJ. Plasma free amino acid profile in cancer patients. Semin Cancer Biol. 2005; 15 (4): 267–76. DOI: 10.1016/J.SEMCANCER.2005.04.003.
  13. Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016; 16 (10): 619–34. DOI: 10.1038/NRC.2016.71.
  14. Youn J, Cho E, Lee JE. Association of choline and betaine levels with cancer incidence and survival: A meta-analysis. Clin Nutr. 2019; 38 (1): 100–09. DOI: 10.1016/J.CLNU.2018.01.042.